आईएसएसएन: 2311-3278
Gabriela Jesús Morón Atencio
Introduction: Candida sp species are fungal pathogens that affect patients with risk pathologies. Due to the change in their conventional drug susceptibility patterns, it is necessary to investigate therapeutic alternatives. It is proposed to evaluate the antifungal potential of nitric oxide (NO), by administering it in the donor s-nitrosomercaptosuccinic acid (MSA-NO), encapsulated in chitosan nanoparticles (Np) to improve its bioavailability and inhibit the growth of Candida albicans, glabrata, krusei and parapsilosis.